NCT07569588Recruiting
Improving Patient Assessment After Acute Kidney Injury (AKI)
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to improve patient care after acute kidney injury (AKI). It has three related parts. The main questions it aims to answer are: 1. Is creatinine or cystatin a more reliable assessment of kidney function after AKI? 2. What are the experiences of patients after AKI? 3. What interventions should be recommended to improve assessment and support of patients after AKI? Participants will be asked to do one or more of: * blood tests to measure kidney function in different ways * have measurement of their body composition * complete questionnaires about their symptoms * have an interview with a researcher about their experiences * discussion to develop an action plan based on findings
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 29 Jan 2026
- Start date
- 16 Feb 2026
- Primary completion date
- 31 Jan 2028
- Lead sponsor
- University of Nottingham
- Diseases
- Chronic kidney disease
- NCT number
- NCT07569588
What you commit to
- Study type: Observational
- Planned participants: 100
- From 16 Feb 2026 to the primary completion date, 31 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current treatment with dialysis
- Renal transplant
- Previous amputation
- Current treatment with dialysis
- Renal transplant
- Receiving palliative care Participatory workshop workstream
Other illness
- Allergy to Omnipaque contrast agent (WP1 only)
Lab values
- No baseline creatinine available in previous 12 months
- No baseline creatinine available in previous 12 months
Other
- Observational study workstream
- Inability to give informed consent
- Pregnancy or breastfeeding
- Pacemaker in situ
- Manifest thyrotoxicosis (WP1 only)
- Ascites or significant (grade 3 to 4) peripheral oedema, defined as ≥6 mm pit, lasting for \>1 minute after 5-second compression over tibia or medial malleolus (WP1 only) Qualitative interview workstream
- Inability to give informed consent
- Inability to give informed consent
- Inability to communicate in English (the qualitative workshops will be held in English)
Who the study is looking for
- Observational study workstream
- Age 18-85 years
- AKI stage 2 or 3 during hospital admission OR AKI stage 1 of at least 7 days duration during hospital admission
- 60-90 days after peak creatinine Qualitative interview workstream
- Age 18-85 years
- AKI during hospital admission
- 60-90 days after peak creatinine Participatory workshop workstream
- Age 18-85 years
- Relevant experience (as assessed by the investigator) which could include personal experience of an episode of hospitalised AKI as a patient of carer, experience of managing AKI or related problems in a professional capacity or knowledge of a particular community.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospitals of Derby and Burton NHS Foundation Trust Coordinator of this site? Confirm its status | Derby | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.